5.20
price down icon0.57%   -0.03
pre-market  Vorhandelsmarkt:  5.36   0.16   +3.08%
loading
Schlusskurs vom Vortag:
$5.23
Offen:
$5.2
24-Stunden-Volumen:
99,396
Relative Volume:
0.01
Marktkapitalisierung:
$9.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.75M
KGV:
-1.60
EPS:
-3.25
Netto-Cashflow:
$-30.91M
1W Leistung:
+8.79%
1M Leistung:
+1,682%
6M Leistung:
+2,005%
1J Leistung:
+72.19%
1-Tages-Spanne:
Value
$5.15
$5.445
1-Wochen-Bereich:
Value
$4.88
$5.45
52-Wochen-Spanne:
Value
$0.224
$10.19

Cellectar Biosciences Inc Stock (CLRB) Company Profile

Name
Firmenname
Cellectar Biosciences Inc
Name
Telefon
(608) 441-8120
Name
Adresse
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Name
Mitarbeiter
11
Name
Twitter
@CellectarBio
Name
Nächster Verdiensttermin
2025-03-05
Name
Neueste SEC-Einreichungen
Name
CLRB's Discussions on Twitter

Vergleichen Sie CLRB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CLRB
Cellectar Biosciences Inc
5.20 13.66M 0 -37.75M -30.91M -3.25
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-05 Fortgesetzt Ladenburg Thalmann Buy
2020-07-01 Eingeleitet Oppenheimer Outperform
2020-01-21 Fortgesetzt ROTH Capital Buy
2019-09-13 Eingeleitet ROTH Capital Buy
2016-12-21 Eingeleitet Ladenburg Thalmann Buy

Cellectar Biosciences Inc Aktie (CLRB) Neueste Nachrichten

pulisher
Jul 22, 2025

Cellectar Biosciences Inc. Stock Analysis and ForecastSpectacular growth rates - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Cellectar Biosciences Inc. stockExceptional trading performance - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Cellectar Biosciences Inc. stock priceHigh-yield portfolio picks - Autocar Professional

Jul 22, 2025
pulisher
Jul 20, 2025

Is Cellectar Biosciences Inc. a good long term investmentConsistently exceptional gains - Autocar Professional

Jul 20, 2025
pulisher
Jul 17, 2025

Cellectar’s Cancer Therapy Hopes Face A Cash Crunch - Finimize

Jul 17, 2025
pulisher
Jul 15, 2025

What makes Cellectar Biosciences Inc. stock price move sharplySafety First Trading Signals - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy - MSN

Jul 15, 2025
pulisher
Jul 15, 2025

How Cellectar Biosciences Inc. stock performs during market volatilityRapid Gain Targets - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Cellectar Biosciences Inc. stock attracts strong analyst attentionFree Stock Market Return Analysis - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight - GlobeNewswire Inc.

Jul 14, 2025
pulisher
Jul 06, 2025

Sequoia Financial Advisors LLC Purchases 188,760 Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World

Jul 06, 2025
pulisher
Jul 03, 2025

Cellectar Biosciences shares rise 3.59% premarket after closing $6.9 million public offering. - AInvest

Jul 03, 2025
pulisher
Jul 02, 2025

Cellectar Biosciences Closes $6.9 Million Public Offering - MarketScreener

Jul 02, 2025
pulisher
Jul 02, 2025

Cellectar Biosciences, Inc. Completes $6.9 Million Public Offering to Advance Cancer Treatment Development - Quiver Quantitative

Jul 02, 2025
pulisher
Jul 02, 2025

Cellectar Biosciences Announces Closing of $6.9 Million - GlobeNewswire

Jul 02, 2025
pulisher
Jul 02, 2025

Cellectar Secures $6.9M Funding: Healthcare Funds Back New Breast Cancer Drug Development - Stock Titan

Jul 02, 2025
pulisher
Jul 01, 2025

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering | CLRB Stock News - GuruFocus

Jul 01, 2025
pulisher
Jul 01, 2025

Cellectar Biosciences prices $6 million public offering - Investing.com

Jul 01, 2025
pulisher
Jul 01, 2025

Cellectar Biosciences, Inc. Announces Pricing of Underwritten Public Offering for Approximately $6 Million - Quiver Quantitative

Jul 01, 2025
pulisher
Jul 01, 2025

Cellectar Biosciences prices $6 million public offering By Investing.com - Investing.com Canada

Jul 01, 2025
pulisher
Jun 30, 2025

Oncology Innovation Just Hit a Turning Point -- Here's What to Watch - The Globe and Mail

Jun 30, 2025
pulisher
Jun 28, 2025

Cellectar Biosciences (NASDAQ:CLRB) Rating Increased to Sell at Wall Street Zen - Defense World

Jun 28, 2025
pulisher
Jun 26, 2025

Cellectar Biosciences, Inc. and Nusano Enter into Multi-Isotope Supply Agreement - MarketScreener

Jun 26, 2025
pulisher
Jun 26, 2025

Cellectar Biosciences provides update on clinical programs and preclinical data - Investing.com

Jun 26, 2025
pulisher
Jun 26, 2025

Cellectar and Nusano sign multi-year radioisotope supply agreement By Investing.com - Investing.com India

Jun 26, 2025
pulisher
Jun 25, 2025

Cellectar Biosciences enacts one-for-thirty reverse stock split on Nasdaq - Investing.com UK

Jun 25, 2025
pulisher
Jun 24, 2025

Cellectar Biosciences (CLRB) Submits Study Protocol to FDA for P - GuruFocus

Jun 24, 2025
pulisher
Jun 24, 2025

Cellectar Biosciences Trading Halted: News Pending - AInvest

Jun 24, 2025
pulisher
Jun 19, 2025

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split - The Manila Times

Jun 19, 2025
pulisher
Jun 18, 2025

Cellectar Biosciences announces one-for-thirty reverse stock split - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Cellectar Biosciences (CLRB) Announces One-for-Thirty Reverse St - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Cellectar Biosciences announces 1:30 reverse stock split - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Cellectar Biosciences (CLRB) Announces Reverse Stock Split | CLR - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Cellectar Biosciences Reports 1-for-30 Reverse Stock Split, Effective June 24 - marketscreener.com

Jun 18, 2025
pulisher
Jun 18, 2025

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split | CLRB Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Cellectar Biosciences, Inc. Announces One-for-Thirty Reverse Stock Split Effective June 24, 2025 - Nasdaq

Jun 18, 2025
pulisher
Jun 16, 2025

Roth Capital Issues Positive Estimate for CLRB Earnings - Defense World

Jun 16, 2025
pulisher
Jun 13, 2025

Cellectar Biosciences Approves Reverse Stock Split Proposal - TipRanks

Jun 13, 2025
pulisher
Jun 11, 2025

Cellectar Biosciences (CLRB) Reports Promising Phase 1 Trial Res - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 - GlobeNewswire

Jun 11, 2025
pulisher
Jun 11, 2025

Cellectar reports improved survival in pediatric brain tumor trial By Investing.com - Investing.com India

Jun 11, 2025

Finanzdaten der Cellectar Biosciences Inc-Aktie (CLRB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Cellectar Biosciences Inc-Aktie (CLRB) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Longcor Jarrod
Chief Operating Officer
Jul 02 '25
Buy
4.99
10,000
49,900
12,768
Kolean Chad J
Chief Financial Officer
Jul 02 '25
Buy
4.99
5,000
24,950
6,418
Longcor Jarrod
Chief Operating Officer
Jan 10 '25
Buy
0.28
30,000
8,400
83,141
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):